JP2021524446A5 - - Google Patents
Info
- Publication number
- JP2021524446A5 JP2021524446A5 JP2020564462A JP2020564462A JP2021524446A5 JP 2021524446 A5 JP2021524446 A5 JP 2021524446A5 JP 2020564462 A JP2020564462 A JP 2020564462A JP 2020564462 A JP2020564462 A JP 2020564462A JP 2021524446 A5 JP2021524446 A5 JP 2021524446A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- composition according
- immunotoxin
- antigen
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024124917A JP2024163118A (ja) | 2018-05-16 | 2024-07-31 | 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862672150P | 2018-05-16 | 2018-05-16 | |
| US62/672,150 | 2018-05-16 | ||
| US201862675263P | 2018-05-23 | 2018-05-23 | |
| US62/675,263 | 2018-05-23 | ||
| US201962844857P | 2019-05-08 | 2019-05-08 | |
| US62/844,857 | 2019-05-08 | ||
| PCT/US2019/032671 WO2019222504A1 (en) | 2018-05-16 | 2019-05-16 | Neoadjuvant cancer treatment with immunotoxin and checkpoint inhibitor combination |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024124917A Division JP2024163118A (ja) | 2018-05-16 | 2024-07-31 | 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021524446A JP2021524446A (ja) | 2021-09-13 |
| JP2021524446A5 true JP2021524446A5 (cg-RX-API-DMAC7.html) | 2022-05-23 |
| JP7536295B2 JP7536295B2 (ja) | 2024-08-20 |
Family
ID=68540816
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564462A Active JP7536295B2 (ja) | 2018-05-16 | 2019-05-16 | 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置 |
| JP2024124917A Abandoned JP2024163118A (ja) | 2018-05-16 | 2024-07-31 | 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024124917A Abandoned JP2024163118A (ja) | 2018-05-16 | 2024-07-31 | 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210214442A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3793585A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7536295B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112423778A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019222504A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12514927B2 (en) | 2019-10-30 | 2026-01-06 | Duke University | Immunotherapy with combination therapy comprising an immunotoxin |
| CN117098539A (zh) * | 2021-03-26 | 2023-11-21 | 阿斯利康(瑞典)有限公司 | 用于黑色素瘤的组合治疗 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US20090269343A1 (en) * | 2008-04-11 | 2009-10-29 | Duke University | Dual Specific Immunotoxin for Brain Tumor Therapy |
| KR20170066546A (ko) * | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| US11065332B2 (en) * | 2015-11-04 | 2021-07-20 | Duke University | Combination therapy of immunotoxin and checkpoint inhibitor |
| EP3411409B1 (en) * | 2016-01-10 | 2025-10-08 | Neotx Therapeutics Ltd. | Anti pd-1/anti-pd-l1 antibodies for enhancing the potency of superantigen mediated cancer immunotherapy |
| WO2017214182A1 (en) * | 2016-06-07 | 2017-12-14 | The United States Of America. As Represented By The Secretary, Department Of Health & Human Services | Fully human antibody targeting pdi for cancer immunotherapy |
| WO2018031507A1 (en) * | 2016-08-09 | 2018-02-15 | Angimmune, Llc | Treatment of cancer using a combination of immunomodulation and check point inhibitors |
| CN109922819A (zh) * | 2016-09-27 | 2019-06-21 | 西莱克塔生物科技公司 | 用于治疗癌症的重组免疫毒素 |
| WO2018075357A1 (en) * | 2016-10-17 | 2018-04-26 | Duke University | PRODUCTION OF IMMUNOTOXIN D2C7-(scdsFv)-PE38KDEL |
| WO2018156448A1 (en) * | 2017-02-21 | 2018-08-30 | The Board Of Regents Of The Uiversity Of Texas System | Prediction and treatment of immunotherapeutic toxicity |
-
2019
- 2019-05-16 CN CN201980032281.XA patent/CN112423778A/zh active Pending
- 2019-05-16 JP JP2020564462A patent/JP7536295B2/ja active Active
- 2019-05-16 EP EP19802992.8A patent/EP3793585A4/en not_active Ceased
- 2019-05-16 WO PCT/US2019/032671 patent/WO2019222504A1/en not_active Ceased
- 2019-05-16 US US17/055,639 patent/US20210214442A1/en not_active Abandoned
-
2024
- 2024-07-31 JP JP2024124917A patent/JP2024163118A/ja not_active Abandoned